Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07145177
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
A Phase 1b Study of 177Lu-PSMA-617 Combined With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
Sponsor: Novartis
Conditions
Metastatic Prostate Cancer Prostate Cancer
Interventions
177Lu-PSMA-617 Ablation Positron Emission Tomography (PET)/Computerized tomography (CT) Questionnaire Trans-arterial chemoembolization (TACE) Tumor Biopsy
Updated 2 times since 2025 Last updated: Dec 10, 2025 Started: Jan 31, 2026 Primary completion: Oct 31, 2028 Completion: Oct 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07145177, this PHASE1 trial focuses on Metastatic Prostate Cancer and Prostate Cancer and remains actively recruiting participants. Sponsored by Novartis, it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Not Yet Recruiting PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Novartis
- University of California, San Francisco
Data source: University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .